One Biosciences
onebiosciences.fr
Actively hiring
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$21.1M
2 rounds on record
Latest round
$3.6M
Venture round · Sep 2026 · this month
Team
10–19
French register · Dec 2024
Revenue
$224k
2025 · French register
Backers
1
Polytechnique-Ventures
The money's age
Fresh money
0 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 11, 2025
Increased its share capital $20k · BODACC
Dec 19, 2021
Increased its share capital $10k · BODACC
Apr 1, 2021
Increased its share capital $6.8k · BODACC
Oct 25, 2020
Increased its share capital $5.4k · BODACC
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2026 | $3.6M | — | YahooFinance |
| Series A | Jul 2025 | $17.5M | Redmile Group lead, Blast lead | YahooFinance |
Registers and programsofficial lists and records that name the company
| Legal entity | One Biosciences SAS | its site |
| Registered | 9 Jun 2020 |
Founders and leadersfrom filings, registers and the company's site
Hedi Ben BrahimDirecteur Généralcompany register
David SchilanskyPrésident de SAScompany register
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
RNA intelligence for precision oncology. Blank Bio builds AI foundation models that help pharma teams identify the right patients for…
With our opti-ox™ technology, we precisely, consistently, & efficiently reprogram stem cells into any cell type at scale for your research…
StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics.
Precision oncology, built for Latin America. Point-of-care software and a multimodal cancer atlas.
At Fever, we’re building the technology needed to make distributed energy work at scale.
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
News
One Biosciences and CHU Nantes advance precision medicine in multiple myeloma with real-time singlecell profiling
The post One Biosciences and CHU Nantes advance precision medicine in multiple myeloma with real-time singlecell profiling appeared first on OneBiosciences.
Read more
Report
One Biosciences Presents Validation Data Supporting First Prospective Study of Real-Time Single-Cell Sequencing of Clinical FFPE Tumor Samples
The post One Biosciences Presents Validation Data Supporting First Prospective Study of Real-Time Single-Cell Sequencing of Clinical FFPE Tumor Samples appeared first on OneBiosciences.
Read more
Report
One Biosciences receives €3,3 Million funding under i-Démo 5 from France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration with Institut Curie
The post One Biosciences receives €3,3 Million funding under i-Démo 5 from France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration with Institut Curie appeared first on OneBiosciences.
Read more
Report
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie
PARIS, September 10, 2026--One Biosciences receives funding to develop the first single-cell profiling diagnostic to inform treatment decisions in triple negative breast cancer
Read more
Report
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples
Read more
Report
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples
Read more
Report
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples
The post One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples appeared first on OneBiosciences.
Read more
Report
One Biosciences Receives BOOST Funding To Advance Single-Cell Assay For ADC Therapies
One Biosciences announced financial support through a Paris-Saclay Cancer Cluster BOOST grant to develop what it describes as the first single-cell assay for antibody-drug conjugate therapies in oncology.
Read more
Report
One Biosciences receives BOOST funding from Paris-Saclay Cancer Cluster to advance the first single-cell assay approach for ADC therapies
The post One Biosciences receives BOOST funding from Paris-Saclay Cancer Cluster to advance the first single-cell assay approach for ADC therapies appeared first on OneBiosciences.
Read more
Report
BiotechTV: Interview of One Biosciences CEO
The post BiotechTV: Interview of One Biosciences CEO appeared first on OneBiosciences.
Read more
Report
Show more news
People
Hedi Ben Brahim
Directeur Général
David Schilansky
Président de SAS
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Paris
France
HQ